Pulmatrix Inc - רווח למניה לשנה מתגלגלת PULM

Pulmatrix, Inc. (PULM) relies on its unique iSPERSE system for pulmonary drug delivery, monetizing patents through strategic partnerships. This chart from GURU.Markets showing the annual change in EPS (TTM) confirms profit dynamics, where 49.80 determines this parameter level. Consistent R&D in antifungal agents is balanced by raw material supply chain risks and geopolitical barriers.

The effectiveness of Pulmatrix, Inc. (PULM) in protecting its iSPERSE intellectual moat for treating pulmonary pathologies is reflected through the measurement of annual EPS TTM growth. This indicator compares net earnings per share over the last four quarters with the same period last year, allowing investors to identify stagnation or acceleration in business capitalization rates, which is critical for assessing startup maturity under FDA regulatory pressure.